Adaptimmune Therapeutics plc (ADAP) Financial Statements (2024 and earlier)

Company Profile

Business Address 60 JUBILEE AVENUE
ABINGDON, OXFORDSHIRE, OX14 4RX
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments204,605369,580368,21789,542205,134208,261
Cash and cash equivalents108,033149,94856,88250,41268,37984,043
Short-term investments96,572219,632311,33539,130136,755124,218
Receivables7,92534,00720,72420,67118,15611,660
Prepaid expense9,4729,0436,3148,3956,2796,120
Other current assets1,9272,082811422439382
Other undisclosed current assets31,4417462,0861,4591,0873,760
Total current assets:255,370415,458398,152120,489231,095230,183
Noncurrent Assets
Operating lease, right-of-use asset18,01920,87518,88020,789
Property, plant and equipment53,51630,49427,77831,06836,11840,679
Intangible assets, net (including goodwill)4421,0001,7302,1981,4731,337
Intangible assets, net (excluding goodwill)4421,0001,7302,1981,4731,337
Restricted cash and investments1,5691,7184,6024,4964,0974,253
Other undisclosed noncurrent assets    2,5033,9534,695
Total noncurrent assets:73,54654,08752,99061,05445,64150,964
TOTAL ASSETS:328,916469,545451,142181,543276,736281,147
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities35,96838,02233,46829,72014,05818,914
Employee-related liabilities   7,5536,592
Accounts payable4,7538,1136,3896,3574,0838,378
Accrued liabilities31,21529,90927,07923,3632,4223,944
Deferred revenue23,52022,1992,8322,128
Debt    2,493  
Deferred revenue and credits38,735
Due to related parties     326
Other liabilities     316357
Other undisclosed current liabilities5,0132,3202,773 10,06315,982
Total current liabilities:64,50162,54139,07334,34124,43774,314
Noncurrent Liabilities
Long-term debt and lease obligation:  23,14820,93822,966  
Liabilities, other than long-term debt182,537177,89649,9045985,4143,849
Deferred revenue160,892177,22349,260 
Other liabilities1,2966736445985,4143,849
Operating lease, liability20,34923,14820,93822,966
Total noncurrent liabilities:182,537201,04470,84223,5645,4143,849
Total liabilities:247,038263,585109,91557,90529,85178,163
Equity
Equity, attributable to parent81,878205,960341,227123,638246,885202,984
Common stock1,3991,3371,325943939854
Additional paid in capital990,656959,611935,706585,623574,208455,401
Accumulated other comprehensive income (loss)(875)(11,142)(10,048)(7,264)(9,763)(21,641)
Accumulated deficit(909,302)(743,846)(585,756)(455,664)(318,499)(231,630)
Total equity:81,878205,960341,227123,638246,885202,984
TOTAL LIABILITIES AND EQUITY:328,916469,545451,142181,543276,736281,147

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues27,1486,1493,9581,12259,50537,833
Revenue, net37,833
Gross profit:27,1486,1493,9581,12259,50537,833
Operating expenses(191,113)(168,395)(137,363)(140,892)(141,870)(118,494)
Operating loss:(163,965)(162,246)(133,405)(139,770)(82,365)(80,661)
Nonoperating income (expense)(536)3,8521,1622,847(12,652)10,974
Investment income, nonoperating   2,7722,8492,230
Other nonoperating income (expense)(536)3,8521,16275(15,501)8,744
Loss from continuing operations before equity method investments, income taxes:(164,501)(158,394)(132,243)(136,923)(95,017)(69,687)
Other undisclosed income from continuing operations before income taxes1,5421,0952,313   
Loss from continuing operations before income taxes:(162,959)(157,299)(129,930)(136,923)(95,017)(69,687)
Income tax expense(2,497)(791)(162)(242)(497)(451)
Loss from continuing operations:(165,456)(158,090)(130,092)(137,165)(95,514)(70,138)
Loss before gain (loss) on sale of properties:(158,090)(130,092)(137,165)(95,514)(70,138)
Net loss available to common stockholders, diluted:(165,456)(158,090)(130,092)(137,165)(95,514)(70,138)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(165,456)(158,090)(130,092)(137,165)(95,514)(70,138)
Comprehensive loss:(165,456)(158,090)(130,092)(137,165)(95,514)(70,138)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent10,267(1,094)(2,784)2,49911,878(7,392)
Comprehensive loss, net of tax, attributable to parent:(155,189)(159,184)(132,876)(134,666)(83,636)(77,530)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: